TTA’s February Valentine: a not-so-funny one for Walgreens, a new HHS Secretary, Amwell lowers the red ink level, PSI helps VA EHR testing, General Catalyst expands wealth management, Fay’s nutritious Series B, more!

 

 

The Big News this week was a new HHS Secretary and a new commission–and over $1 billion in awards and penalties adding to Walgreens’ red ink. While Amwell lowers the red ink level, VA gets more testing help for the Oracle EHR resumed rollout from PSI. General Catalyst expands into wealth management for rich entrepreneurs. Fay’s Series B the only funding this week of note.

News roundup 2: RFK Jr. confirmed as HHS Secretary, new MAHA commission formed; Amwell narrows loss by 68%; HEALWELL (CA) nears close of Orion Health (NZ) buy; Summer Health buys Caraway; Spectrum.Life (IE) plans to double users; 2025 NY Digital Health 100 announced (A grab-bag of news)
News roundup: PSI awarded $156M contract for VA EHR testing; $50M for Fay nutrition; General Catalyst’s wealth management expansion; UniDoc’s HealthCube debuts in Ukraine (GC Wealth adds to cornering VC funding)
This just in: New York State nicks Walgreens’/VillageMD’s CityMD for $14M+ in refunds, canceled debt on improper Covid-19 billing (Can’t catch a break)
Walgreens’ misery level rises some more: Federal court affirms $987M award to PWNHealth/Everly Health. Plus selling $295M in Cencora shares, drawing down to 6%. (More hits to the bottom line)

The shape of 2025 starts to show with which companies bet, hold, and fold. More and more AI deployments (at least termed that way) including a massive NHS trial. More fundings at better levels. Teladoc surprises and buys a company. Sword Health adding telemental health. But the holds and folds are evident in both Veradigm and Evolent Health going off the block, Walgreens suspending dividends after 91 years, and Transcarent maybe folding their 98point6 telehealth service?

News roundup: NHS announces EDITH breast cancer screening trial, Sword Health reveals mental health move in AI-first push, Evolent Health changes up board, Highmark’s enGen tech drops 208 (More and more AI)
Teladoc to buy Catapult Health in all-cash, $65 million deal (First buy since Livongo)
The table stacks–and clears: fundings for RadAI $60M, The Helper Bees $35M, Bicycle Health $16.5M. Walgreens suspends stock dividends after 91 years. And has Transcarent zeroed out 98point6? (The real start of the year)
This just in #2: Masimo board director Bob Chapek resigns (When you wish upon a star…)
This just in: Veradigm gives up on finding buyer, brings in ‘strategic advisory’ firm for “standalone” future (Surprised?)

A relatively quiet week that included only one significant acquisition and one product introduction. Three inevitables: cash-poor 23andMe needs a rescuer, Masimo and former CEO Kiani continue to sue and countersue, and UnitedHealthcare has a new CEO. 

News roundup: UnitedHealthcare names new president, Neuroflow buys Quartet Health, Owlet intros Owlet 360 (A mysterious sale by Quartet)
23andMe running low on cash, considers sale, “strategic alternatives” by Special Committee (The Perils of Anne Wojcicki, now on the tracks)
Round 2: Masimo former CEO Kiani counters Masimo lawsuits in New York, Delaware (Suits! Countersuits!)

Epic changes in DC are reverberating through HHS–and telehealth. It won’t be business as usual for Walgreens with a bombshell Federal illegal Rx dispensing lawsuit, nor UnitedHealth getting pressed by investors on denied claims. 23andMe may decide to do without Lemonaid, while Masimo recovers with a new CEO. Fundings and M&A get interesting. Quite a change from the ‘down round’ that was 2024 in Rock Health’s report!

Updates: ATA on telehealth policy priorities, UHG investor group demands denied care report, DOJ sues Walgreens on illegal Rx dispensing, VA nominee supports Oracle EHR deployment, RFK Jr. HHS nomination hits Senate (Not good news for UHG and Walgreens)
2024 another ‘down round’ for US digital health funding, with smaller deals and earlier stages: Rock Health (Concentrating–and less $)
Funding/M&A roundup: DarioHealth’s $25M, Innovaccer buys Humbi AI, Percipio Health launches with a $20M Series A, Iris Telehealth buys innovaTel (’25 steady so far)
Perspectives: Three Strategies to Bring Digital-First Care to Patients Through Telehealth 
Masimo names new CEO, new board chair and vice chair. And confirms a fresh direction. (Politan’s big bet))
Straws in the wind? 23andMe considering Lemonaid telehealth sale, announces Discover23 research offering with Lifebit (Shrinking and pivoting before ?)

Now past the ‘happy new year’ greetings, it’s time for the 2024 financial reports and 2025 forecasts–some good, some not. Companies are scoring decent raises for the first time in two years, while PE General Catalyst is cutting deals with AWS. M&A activity concentrates on consolidation and integration. And we highlight two social companions for seniors’ tabletops.

2024 earnings roundup: UnitedHealth Group and Masimo (Closing out an annus horribilis)
Short takes: UK’s Cera raises $150M, $105M for Qventus, Solera Health’s $40M; General Catalyst’s AWS deal, Virta Health hits $100M in revenue, powered by GLP-1 maintenance; VirtuAlly’s JC telehealth accreditation
M&A consolidation + integration continues with Health Catalyst-Upfront Healthcare, New Mountain-Access Healthcare and Machinify, SuperDial-Major Boost (As predicted)
Walgreens’ kicks off FY 2025 with a wider net loss of $265M; shares rise 25% as closures, sales, and cost-cutting continue (Prelude to a sale?)
AI-powered senior companions hit the tabletops at CES: ElliQ’s Caregiver Solution, ONSCREEN Joy (Making social communication easier for older people)

Our opening was devoted to rounding up the inter-holiday period and looking forward to 2025. 2024’s end held a few sneaky surprises such as NeueHealth going private via investor NEA, another General Catalyst consolidation, and a few more under the wire fundings. Not surprising was UHG and Amedisys extending their runway–as well as VA with Oracle Health rollouts. Looking at 2025, Walgreens and their inevitable sale, experts predict, and Glen Tullman’s Transcarent buys up the competition. 

News roundup #2: why Walgreens is considering selling to a PE, December fundings, 2024’s surprises, M&A ’25 predictions, Transcarent buying Accolade for $621M (Why should Glen Tullman wait on a big buy?)
News roundup #1: UHG-Amedisys extended, NeueHealth going private in NEA’s ‘deal deal’, Commure buying Memora Health, VA resuming Oracle rollouts–now mid-’26 (NeueHealth continues to defy gravity and Reality)

We wound it up for 2025 with a year’s end newsletter to our Readers with a few Quirky Predictions and some Santa Wishes. A lot of news around telehealth in the continuing US budget wrangle that was finally passed for a few months, raises making it inside the 2024 wire, UHG sued by Nebraska over Change and insider trading, Redesign Health’s fresh funding, Withings’ new BPM, removing language barriers using telehealth, and quite a bit more.

A year’s end newsletter to our Readers: a few wishes for Under the Tree, a few Quirky Predictions for 2025  (We stay true to being opinionated!)
News roundup: Precision’s $102M raise, more on BCI; Withings clears BPM Pro 2; Nebraska 1st state to sue Change/UHG, related insider trading update; VA Oracle go-lives may resume; ATA intros CODE; ClearDATA HITRUST certified (UHG’s Mound of Misery grows)
Rounding up last of 2024’s M&A/fundings: Redesign Health’s $175M, HEALWELL AI buys Orion Health, startup Tuva Health’s $5M (In the bank for 2024)
Federal budget continuing resolution battle could derail or delay telehealth extensions, physician fee increase, PBM reforms (updated 19 Dec) (Cut down by 90%, it may pass)
Perspectives: How Telehealth is Transforming Access for Limited English Proficiency (LEP) Patients (Removing a critical barrier)


Have a job to fill? Seeking a position? See jobs listed with our job search partner Jooble in the right sidebar!


Read Telehealth and Telecare Aware: https://telecareaware.com/  @telecareaware

Follow our pages on LinkedIn and on Facebook

We thank our advertisers and supporters: Legrand, UK Telehealthcare, ATA, The King’s Fund, DHACA, HIMSS, MedStartr, and Parks Associates.

Reach international leaders in health tech by advertising your company or event/conference in TTA–contact Donna for more information on how we help and who we reach. 


Telehealth & Telecare Aware: covering the news on latest developments in telecare, telehealth, telemedicine, and health tech, worldwide–thoughtfully and from the view of fellow professionals

Thanks for asking for update emails. Please tell your colleagues about this news service and, if you have relevant information to share with the rest of the world, please let me know.

Donna Cusano, Editor In Chief
donna.cusano@telecareaware.com

– – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –

News roundup 2: RFK Jr. confirmed as HHS Secretary, new MAHA commission formed; Amwell narrows loss by 68%; HEALWELL (CA) nears close of Orion Health (NZ) buy; Summer Health buys Caraway; Spectrum.Life (IE) plans to double users; 2025 NY Digital Health 100 announced

Robert F. Kennedy, Jr. was confirmed this morning as US Health and Human Services (HHS) Secretary. The Senate vote was fairly standard for President Trump’s appointees, along party lines (with one exception) in a 52-48 vote. Secretary Kennedy survived bare-knuckle committee hearings (and a family ‘diss’ from cousins) to put into place measures to Make America Healthy Again (MAHA) as promised during the 2024 presidential campaign. Today’s presidential Executive Order also makes Secretary Kennedy the leader of the MAHA Committee, which, according to a White House statement will be “tasked with investigating and addressing the root causes of America’s escalating health crisis, with an initial focus on childhood chronic diseases.” such as autism and fatty liver disease, plus adult asthma and the causes of the low US life expectancy.  The EO’s four policy directives focus on reversing chronic disease through:

  1. transparency on health data to “avoid conflicts of interest in all federally funded health research
  2. prioritizing “gold-standard research on why Americans are getting sick” in all federally-funded health research
  3. working with farmers to ensure food is healthy as well as affordable
  4. expanding health coverage and treatment options “for beneficial lifestyle changes and disease prevention.”

The timeframe is short: 100 days to produce an initial assessment, and 180 days to produce a strategy to improve child health. All this and learn HHS too. Next up in hearings: Mehmet Oz, MD as CMS Administrator, expected to face far less flak.  FoxNewsDigital

Amwell straining to get weller, financially. Still in the red but improving by about 68%, Amwell’s full year 2024 net loss was $212.6 million on $254 million in revenue versus 2023’s net loss of $679.2 million, which included a non-cash goodwill impairment charges of $436.5 million. Taking away the one-time charge though, the loss improvement was $31 million.

Q4 had a strong 36% improvement in subscription revenue versus prior year, driven by the implementation of a 22-month joint contract with technology firm Leidos to digitize the Military Health System (MHS). However, this contract expires in July and given cost-cutting in Washington, is not assured of renewal. Leidos is already in negotiation with the Department of Defense for a three-year extension. In cost reduction, Amwell reduced R&D expenses by 29% and looks at further cuts for 2025 of 10%.

For 2025, Amwell forecasts revenue in the range of $250 to $260 million, including the previously announced divestiture of Amwell
Psychiatric Care, about $30 million) with adjusted EBITDA loss between $55 to $45 million. Positive cash flow is not forecast until 2026. But Amwell’s share price, in such a hole that the NYSE threatened delisting a year ago, has bounced from below $8 in January to closing at $11.73 today (13 February).  Amwell 2024 financial report, Healthcare Dive

HEALWELL AI one step closer to closing its purchase of Orion Health. HEALWELL needed consent from New Zealand’s Overseas Investment Office of New Zealand (OIO) to proceed with the purchase announced in December [TTA 19 Dec 2024]. HEALWELL is an artificial intelligence company focused on preventative care through the early identification and detection of disease while Orion’s products–Orchestral, Amadeus, and Virtuoso–are data exchange, patient record, and analytics platforms that benefit clinicians and patients. The complex buy totaled NZ$200 million/CA$165 million (US$115 million) for 100% of Orion’s private shares. CA$86 million will be paid in cash and the balance will be paid in HEALWELL stock plus CA$20.5 million in a 3-year performance-based arrangement. The companies are now on track to complete the sale by 1 April. Newsfile release

Summer Health buys Caraway. Summer is a text service that connects parents with pediatricians for urgent care through texting and converts doctor’s and clinical notes into lay language via generative AI. Caraway served a different market–Generation Z women between 18-29 for mental and reproductive health. What they did share was one investor: the powerful 7Wire Ventures. Was this another Shotgun Merger? While Caraway enjoyed an initial funding of over $10 million plus $16 million during the 2023 slump, apparently it had ceased business in December and took its website offline. How Summer positions it is that it now can serve children, teens, and young adults. In addition to its 50-state DTC direct pay service, it will pick up Caraway’s insurance contracts. There are no references to purchase price or workforce transitions. Other than the release, there’s no reference to Caraway services on the Summer website. Summer had a Series A raise of $11 million last April.    Summer release, Behavioral Health Business  Hat tip to Mario Aguilar of STAT Health Tech’s newsletter.

Following up on Ireland’s Spectrum.LifeThey ended their 2024 serving 1.5 million users and project 3 million in 2025 in Ireland and the UK. Spectrum.Life now has 300 employees in Dublin and Manchester delivering digital health, mental health, and wellbeing for employers and employees in the workplace, insurers, and educators. Last year it was listed as #41st in Deloitte Ireland’s 2024 Technology Fast 50 Awards. Release.

And a bit closer to the Editor’s home is the latest New York Digital Health 100. Named by Digital Health New York (DHNY) and in its sixth year (oh, the changes!), the list has 48 new startups (which is illustrative of the churn in the NY digital health scene) these 100 companies raised about $4 billion, with over half going to biotech (26%), care delivery (24%), and mental health (13%) companies. A download of the full report and lists is available at the above link.

Rounding up last of 2024’s M&A/fundings: Redesign Health’s $175M, HEALWELL AI buys Orion Health, startup Tuva Health’s $5M

The largest of the year-end fundings (so far) goes to Redesign Health. Best described as a designer and funder of startup health companies which are then spun off, Redesign gained a $175 million investment for a new fund from Declaration Partners, Euclidean Capital, and True North Advisors. Unlike your typical seed funder or incubator, Redesign takes an activist role in forming startups before spinning them off. Its model includes in-house experts to advise on formation, connecting the startup to existing relationships with healthcare organizations and demand generation systems, and access to networks of investors and talent experts. Redesign has used this model with more than 60 companies. These companies have had over 15 million patients and generated >$1 billion of revenue. The fresh funding will be used to start up new companies in eight areas, including ‘preparing for an aging population’. Release, MedCityNews 

Once spun off, the organizations are on their own. Some have been acquired: Jabra Enhance in hearing aids (GN Hearing) and Vault Workforce Screening (Sterling). One notably got into trouble–Calibrate, which was sold for $20 million in an October 2023 ‘reorganization’ to private equity firm Madryn Asset Management along with other investors [TTA 26 Oct 2023]. A pioneer in DTC telehealth programs for GLP-1 weight loss drugs, Calibrate was caught in the squeeze between scarcity of those drugs (Ozempic, Wegovy) and the entry of Teladoc, unable to fulfill its programs nor, at that time, to get insurance reimbursement. It is now benefiting from being in a very hot sector of weight loss drugs. Prior to the sale, Calibrate raised about $160 million in funding [TTA 15 Feb]. Interestingly, Calibrate is still listed in the Redesign portfolio including career openings.

Redesign itself had some rocky times earlier this year with their layoff of 77 from their New York-based staff of 200 to 250 (estimated). The cuts were from the areas that support new venture creation. The new funding is the first sign that Redesign is getting back into the business of forming new companies versus maintaining the portfolio.

New Zealand’s Orion Health to be acquired by Canada’s HEALWELL AI. The final price is NZ$200 million/CA$165 million (US$115 million) for 100% of Orion’s private shares. CA$86 million will be paid in cash and the balance will be paid in HEALWELL stock plus CA$20.5 million in a 3-year performance-based arrangement. Closing is anticipated to be April 2025, after Orion divests itself of non-strategic assets and the usual approvals by shareholders, regulators, and the Toronto Stock Exchange.

Orion Health’s products–Orchestral, Amadeus, and Virtuoso–are data exchange, patient record, and analytics platforms to benefit clinicians and patients. Their largest customers are in Canada, Australia, and New Zealand, plus the NHS in the UK, giving HEALWELL AI an international footprint. HEALWELL AI is based in Toronto and is an artificial intelligence company focused on preventative care through the early identification and detection of disease. Their release announcing the transaction is interesting because of the complexity of the funding (dare we say leveraged?). HEALWELL has $47.6 million in funding over six rounds (Crunchbase). It trades in the vicinity of CA$ 2.00 which gives it a valuation of CA$354 million. Mobihealthnews

Orion Health was last mentioned here with their win two years ago of Saudi Arabia’s health information exchange. The founder, Ian McCrae for the past 30 years, stepped down in August 2022 for health reasons. Replacing him was Brad Porter, his son-in-law. 

On the other end of the spectrum, Tuva Health emerges from stealth with $5 million. The round was led by Virtue, with participation from Box Group and Y Combinator, and notable health tech angel investors. New York-based Tuva has an open-source data model for healthcare analytics and data management to be used by healthcare providers, payers, life sciences companies, and research institutions as an open standard for healthcare data transformation. Their software gives users the ability to transform claims and EHR datasets into analytics-ready data tables via an open-source data model with built-in normalization, data quality testing, and enrichment. 1,500 experts are currently working in collaboration on the model. Their initial partnerships are with Oscar Health and CareAbout Health.  The principals and founders, Aaron Neiderhiser and Coco Zuloaga, are former senior executives from Health Catalyst and Strive Health. Release, FierceHealthcare